DUBLIN - June 19, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its schedule of notable sessions that will be presented at the 78th Scientific Sessions of the American Diabetes Association, in Orlando, June 22-26. A significant portion of the scientific data being presented focuses on Medtronic's insulin pump systems, including the MiniMed(TM) 670G system, the world's first hybrid closed-loop system. Data will also be presented on the Sugar.IQ(TM) app, powered by IBM Watson technology, as well as managing glucose control using the Guardian(TM) Connect continuous glucose monitoring (CGM) system.

Scientific Presentations

Cognitive Science

- "Real-World Assessment of Sugar.IQ with Watson: A Cognitive Computing-Based Diabetes Management Solution" - oral presentation by Yuxiang Zhong on Friday, June 22 from 6 - 6:15 p.m. W311, 16-OR.

Continuous Glucose Monitoring (CGM)

- "Real-world Avoidance of Glucose Excursions with the Guardian Connect CGM System's Predictive Alerts" - poster presentation by Sinu Bessy Abraham on Saturday, June 23 from 11:30 a.m. - 12:30 p.m. Poster Hall, 953-P.

- "Fourth-Generation Glucose Sensor with an Advanced Algorithm Featuring No Calibrations and Optional Calibration Modes of Operation" - poster presentation by Dr. Andrea Varsavsky on Saturday, June 23 from 11:30 a.m. - 12:30 p.m. Poster Hall, 936-P.

Insulin Pump Therapy

- "Real-World Data from the MiniMed 670G System Commercial Launch: Patients Previously Using MDI Therapy" - oral presentation by Dr. Scott W. Lee on Sunday, June 24 from 3 - 3:15 p.m. W308, 209-OR.

- "Real-World Data from the MiniMed 670G System Commercial Launch" - poster presentation by Pratik Agrawal on Sunday, June 24 from 12 - 1 p.m. (Poster Hall, 960-P and 994-P covering 1,052 patients) and a moderated poster presentation on Monday, June 25 from 12-1 p.m. (ePoster Theater B, 960-P).

- "The MiniMed 670G Hybrid Closed-Loop (HCL) System and Patient-Reported Outcomes Concerning Quality of Life Measures" - poster presentation by Shweta Gopalakrishnan on Sunday, June 24 from 12 - 1 p.m. (Poster Hall, 963-P) and moderated poster presentation on Monday, June 25 from 12 - 1 p.m. (ePoster Theater B, 663-P).

- "Overnight Insulin Delivery and Glucose in Children Using the MiniMed 670G System" - oral presentation by Dr. Anirban Roy on Sunday, June 24 from 2:15 - 2:30 p.m. W308, 206-OR.

- "Overnight to Early-Morning Glycemic Outcomes in Children Using the MiniMed 670G Hybrid Closed-Loop (HCL) System" - oral presentation by Dr. Gregory P. Forlenza on Sunday, June 24 from 6 - 6:15 p.m. W204, 236-OR.

- "Characterization of the Predictive Low Glucose Management (PLGM) Algorithm of the MiniMed 670G System in Children" - poster presentation by Dr. Dorothy I. Shulman on Sunday, June 24 from 12 - 1 p.m (Poster Hall, 965-P) and moderated poster presentation on Monday, June 25 from 12-1 p.m. (ePoster Theater B, 965-P).

- "Postprandial Response in Children Using the MiniMed 670G System" - poster presentation by Dr. Di Wu on Sunday, June 24 from 12 - 1 p.m. Poster Hall, 969-P.

- "MiniMed Veo(TM) Insulin Pump Analysis for Real-World Non-Adjunctive CGM Insights" - poster presentation by Dr. Robert A. Vigersky on Saturday, June 23 from 11:30 a.m. - 12:30 p.m. Poster Hall, 920-P.

Company Exhibit Floor Presentations
Medtronic will be showcasing their newest and most advanced technologies at Booth #639, including the MiniMed 670G system as well as the Guardian Connect continuous glucose monitoring (CGM) system with the Sugar.IQ intelligent diabetes assistant app.

Additionally, Medtronic will host a series of presentations at the booth from Saturday through Monday, providing an opportunity for attendees to learn about the application of Medtronic technologies from experts. A full list of presentations is below:

- MiniMed 670G System Real World Data & Patient Stories - Saturday, June 23 at 10:30 a.m. and Sunday, June 24 at 1:30 p.m.

- Digital Therapeutics: Improving Adherence and Outcomes - Saturday, June 23 at 3 p.m.

- Creating Personalized Treatment Plans Through iPro(TM)2 Professional CGM - Sunday, June 24 at 10:30 a.m.

- Guardian Connect CGM & Sugar.IQ Insights - Sunday, June 24 at 3 p.m. and Monday, June 25 at 10:30 a.m. and 1:30 p.m.

Finally, Medtronic will also be hosting two Product Theater Presentations. The date and time for each presentation is as follows:

- "The Guardian Connect System: Utilizing predictive alerts and data backed insights to help with diabetes management" - presented by Dr. Timothy S. Bailey and Huzefa Neemuchwala on Sunday, June 24 at 10:15 a.m.

- "MiniMed 670G System: Increasing time in range with automated insulin delivery" - presented by Drs. Anders L. Carlson and Jennifer L. Sherr on Monday, June 25 at 10:15 a.m.

Analyst and Investor Briefing
Medtronic will host a webcast to highlight its Diabetes Group on Monday, June 25, from 9 a.m. to 10 a.m. EDT. The webcast will feature remarks from Medtronic management, including comments on Medtronic's clinical data, product pipelines, and market outlooks. The live audio webcast can be accessed by clicking on the Investor Events link at http://investorrelations.medtronic.com on June 25. Within 24 hours of the webcast, a replay will be available on the same webpage. This event is not part of the official ADA Scientific Sessions.

Sponsored Events
Medtronic is also proud to serve as a sponsor for three events at this year's ADA:

- Women Interprofessional Networking (WIN) ADA Networking Reception - taking place Friday, June 22 from 6:30 - 8:30 p.m. EDT at the Orange County Convention Center in the Third Level Foyer

- 12th Annual Diabetes Forum - taking place on Monday, June 25 from 6:30 - 8:30 p.m. at the Rosen Centre Hotel

- Musings Under the Moon - taking place on Monday, June 25 from 9:30 p.m. - 1:30 a.m. at BB King's Blues Club

About the Diabetes Group at Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 86,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

Contacts:
Janet Cho
Public Relations
+1-818-576-5014

Ryan Weispfenning
Investor Relations
+1-763-505-4626

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Medtronic plc via Globenewswire